AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18955748 — intervention group
Group type: EXPERIMENTAL
Intervention: Using arms and legs simultaneously
Number of subjects: 16
Study 18955748 — intervention group
Group type: COMPARATOR
Intervention: Front drive-axis wheelchair
Number of subjects: 16
Study 18955748 — intervention group
Group type: COMPARATOR
Intervention: Using arms only
Number of subjects: 16
Study 18955748 — intervention group
Group type: COMPARATOR
Intervention: Using legs only
Number of subjects: 16
Study 17140945 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilutional conventional ultrafiltration (group D)
Number of subjects: 60
Study 17140945 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (group M)
Number of subjects: 60
Study 17140945 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dilutional conventional and modified ultrafiltration (group B)
Number of subjects: 60
Study 17140945 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 60
Study 12689799 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Pap smear plus mammogram reminders
Number of subjects: 2471
Study 12689799 — intervention group
Group type: COMPARATOR
Intervention: Mammogram-only reminders
Number of subjects: 2471
Study 10325852 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide pneumoperitoneum
Number of subjects: 28
Study 10325852 — intervention group
Group type: COMPARATOR
Intervention: Abdominal wall lifting
Number of subjects: 28
Study 10325852 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic appendectomy
Number of subjects: 28
Study 10325852 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 28
Study 8523135 — intervention group
Group type: EXPERIMENTAL
Intervention: V/Q lung scan interpreted as normal
Number of subjects: 0
Study 8523135 — intervention group
Group type: EXPERIMENTAL
Intervention: V/Q lung scan interpreted as very low, low, or high probability of PE
Number of subjects: 0
Study 8523135 — intervention group
Group type: EXPERIMENTAL
Intervention: V/Q lung scan interpreted as intermediate probability of PE
Number of subjects: 0
Study 8523135 — intervention group
Group type: EXPERIMENTAL
Intervention: V/Q lung scan with discordant clinical likelihood of PE
Number of subjects: 0
Study 1952847 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin hydrochloride (400 mg once a day for 7 days)
Number of subjects: 400
Study 1952847 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim (160 mg) and sulfamethoxazole (800 mg) (TMP-SMZ) twice daily for 10 days
Number of subjects: 400
Study 7026971 — intervention group
Group type: EXPERIMENTAL
Intervention: Methandrostenolone
Number of subjects: 0
Study 7026971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30368852 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 183
Study 30368852 — intervention group
Group type: COMPARATOR
Intervention: Individual treatment
Number of subjects: 183
Study 30321520 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibuprofen (800 mg)
Number of subjects: 58
Study 30321520 — intervention group
Group type: COMPARATOR
Intervention: IV acetaminophen (1000 mg)
Number of subjects: 58
Study 27344987 — intervention group
Group type: EXPERIMENTAL
Intervention: Compounded dexamethasone mouth rinse
Number of subjects: 9
Study 27344987 — intervention group
Group type: COMPARATOR
Intervention: Existing therapy (self-formulated dexamethasone mouth rinse)
Number of subjects: 9
Study 25660225 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS‐TBNA)
Number of subjects: 133
Study 25660225 — intervention group
Group type: COMPARATOR
Intervention: Conventional diagnosis and staging (CDS)
Number of subjects: 133
Study 23302603 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 2312
Study 23302603 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher diastolic blood pressure (BP)
Number of subjects: 2312
Study 23302603 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol level
Number of subjects: 2312
Study 21272091 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin at 4 mg twice a day
Number of subjects: 136
Study 21272091 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin at 0.2 mg once a day
Number of subjects: 136
Study 21272091 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil at 50 mg once a day
Number of subjects: 136
Study 19541816 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 2102
Study 16772812 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg/d
Number of subjects: 14
Study 16772812 — intervention group
Group type: COMPARATOR
Intervention: Control group without amantadine
Number of subjects: 14
Study 15585759 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter meal (38% SFAs, 22% MUFAs, 4% PUFAs, and 0.7% alpha‐linolenic acid)
Number of subjects: 8
Study 15585759 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut meal (20% SFAs, 24% MUFAs, 16% PUFAs, and 4% alpha‐linolenic acid)
Number of subjects: 8
Study 15585759 — intervention group
Group type: COMPARATOR
Intervention: Olive oil meal (22% SFAs, 38% MUFAs, 4% PUFAs, and 0.7% alpha‐linolenic acid)
Number of subjects: 8
Study 15585759 — intervention group
Group type: COMPARATOR
Intervention: All meals (olive oil, butter, walnut)
Number of subjects: 8
Study 12905865 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 89
Study 12905865 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 89
Study 12905865 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 89
Study 9131756 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded subjective rankings
Number of subjects: 0
Study 8361890 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin, furosemide, nifedipine (N)
Number of subjects: 46
Study 8361890 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin, furosemide, isosorbide dinitrate (S)
Number of subjects: 46
Study 8361890 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin, furosemide, isosorbide dinitrate (S) and captopril (K)
Number of subjects: 46
Study 3499154 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 cGy total lymphoid irradiation (TLI)
Number of subjects: 13
Study 3499154 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone therapy
Number of subjects: 13
Study 3499154 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 13
Study 3499154 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 13
Study 3499154 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster occurrence
Number of subjects: 13
Study 31809827 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0
Study 29287276 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive measures (e.g., the use of a 'soft room', observation in seclusion)
Number of subjects: 264
Study 29287276 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive measures (e.g., mechanical restraint, forced medication)
Number of subjects: 264
Study 29287276 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced medication and mechanical restraint
Number of subjects: 264
Study 29287276 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective understanding of coercive measures
Number of subjects: 264
Study 29287276 — intervention group
Group type: EXPERIMENTAL
Intervention: Options for reducing coercion (e.g., music or exercises)
Number of subjects: 264
Study 26198283 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with diluted epinephrine and 0.5% dexamethasone (LED)
Number of subjects: 240
Study 26198283 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with diluted epinephrine (LE)
Number of subjects: 240
Study 26198283 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline (S)
Number of subjects: 240
Study 26198283 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) without BAL
Number of subjects: 240
Study 25448515 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of intramuscular 17OHP‐C weekly until 36 weeks
Number of subjects: 105
Study 25448515 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 105
Study 25448515 — intervention group
Group type: EXPERIMENTAL
Intervention: 17OHP‐C
Number of subjects: 105
Study 25448515 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 23346989 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected music
Number of subjects: 100
Study 23346989 — intervention group
Group type: COMPARATOR
Intervention: No music (control)
Number of subjects: 100
Study 20559296 — intervention group
Group type: COMPARATOR
Intervention: Placebo + BMOD (N = 202)
Number of subjects: 793
Study 20559296 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone SR (32 mg/day) + Bupropion SR (360 mg/day) + BMOD (N = 591)
Number of subjects: 793
Study 20559296 — intervention group
Group type: COMPARATOR
Intervention: Placebo + BMOD (N = 193)
Number of subjects: 793
Study 20559296 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone SR (32 mg/day) + Bupropion SR (360 mg/day) + BMOD (N = 482)
Number of subjects: 793
Study 20559296 — intervention group
Group type: COMPARATOR
Intervention: Placebo + BMOD (N = 106)
Number of subjects: 793
Study 20559296 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone SR (32 mg/day) + Bupropion SR (360 mg/day) + BMOD (N = 301)
Number of subjects: 793
Study 20559296 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone SR (32 mg/day) + Bupropion SR (360 mg/day) + BMOD
Number of subjects: 793
Study 18359326 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and Ezetimibe
Number of subjects: 1758
Study 18359326 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1758
Study 16553529 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 286
Study 16553529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 14606739 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (eight-week programme using a leg cycle ergometer)
Number of subjects: 92
Study 14606739 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 92
Study 10392861 — intervention group
Group type: EXPERIMENTAL
Intervention: Poloxamer 188 as ancillary therapy to thrombolysis
Number of subjects: 74
Study 10392861 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 74
Study 8707981 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% delmopinol mouthwash
Number of subjects: 450
Study 8707981 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% delmopinol mouthwash
Number of subjects: 450
Study 8707981 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 450
Study 1846784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg/24 hr
Number of subjects: 10
Study 1846784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 640 mg/24 hr
Number of subjects: 10
Study 1846784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 10
Study 6295691 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mmol sodium intake
Number of subjects: 9
Study 6295691 — intervention group
Group type: COMPARATOR
Intervention: 200 mmol sodium intake
Number of subjects: 9
Study 30625242 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality, intensive early childhood program
Number of subjects: 0
Study 29374881 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperandrogenic PCOS
Number of subjects: 484
Study 29374881 — intervention group
Group type: COMPARATOR
Intervention: Normoandrogenic PCOS
Number of subjects: 484
Study 27401037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol (Group VitD2)
Number of subjects: 204
Study 27401037 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol (Group aVitD3)
Number of subjects: 204
Study 27401037 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 204
Study 23681677 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child interaction therapy (immediate treatment)
Number of subjects: 28
Study 23681677 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 28
Study 22543069 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial nerve block in the popliteal fossa
Number of subjects: 80
Study 22543069 — intervention group
Group type: COMPARATOR
Intervention: Sciatic nerve block combined with femoral nerve block
Number of subjects: 80
Study 22543069 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial nerve block
Number of subjects: 80
Study 22543069 — intervention group
Group type: COMPARATOR
Intervention: Sciatic nerve block
Number of subjects: 80
Study 22543069 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial nerve block and Sciatic nerve block
Number of subjects: 80
Study 20166415 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Single Bond Plus (ASB) - two‐step etch‐and‐rinse
Number of subjects: 200
Study 20166415 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Scotchbond SE (AS) - two‐step self‐etch
Number of subjects: 200
Study 20166415 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CSE) - two‐step self‐etch
Number of subjects: 200
Study 20166415 — intervention group
Group type: EXPERIMENTAL
Intervention: XENO V (X) - one‐step self‐etch
Number of subjects: 200
Study 20166415 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Easy Bond (AE) - one‐step self‐etch
Number of subjects: 200
Study 20166415 — intervention group
Group type: COMPARATOR
Intervention: Control - high C-factor mold
Number of subjects: 200
Study 18580176 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive-support ventilation (ASV)
Number of subjects: 50
Study 18580176 — intervention group
Group type: COMPARATOR
Intervention: Pressure-regulated volume-controlled ventilation with automode (PRVCa)
Number of subjects: 50
Study 16821204 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN), 10 mg daily for 2 years
Number of subjects: 19
Study 11918754 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 177
Study 11918754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 9647536 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting GnRHa (leuprolide acetate)
Number of subjects: 183
Study 9647536 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting GnRHa (leuprolide acetate)
Number of subjects: 183
Study 9647536 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting GnRHa (tryptorelin)
Number of subjects: 183
Study 9647536 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 183
Study 7734258 — intervention group
Group type: EXPERIMENTAL
Intervention: 51W89 (0.1 mg kg‐1, 2 x ED95)
Number of subjects: 32
Study 7734258 — intervention group
Group type: COMPARATOR
Intervention: Atracurium (0.4 mg kg‐1)
Number of subjects: 32
Study 7734258 — intervention group
Group type: EXPERIMENTAL
Intervention: 51W89
Number of subjects: 32
Study 2789932 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (14 mg)
Number of subjects: 0
Study 2789932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4154818 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride topical application twice a year (Group 3)
Number of subjects: 497
Study 4154818 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride topical application once a year (Group 2)
Number of subjects: 497
Study 4154818 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 497
Study 29432772 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (L. acidophilus, L. plantarum, L. fermentum, L. gasseri with fructooligosaccharide for 6 weeks)
Number of subjects: 90
Study 29432772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 26031995 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise
Number of subjects: 202
Study 26031995 — intervention group
Group type: COMPARATOR
Intervention: Physical activity
Number of subjects: 202
Study 24417565 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered checklist
Number of subjects: 32
Study 24417565 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 32
Study 23652044 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg/m2 gambogic acid intravenously from Days 1 to 5 of a 2-week cycle (Group A)
Number of subjects: 47
Study 23652044 — intervention group
Group type: COMPARATOR
Intervention: 45 mg/m2 gambogic acid every other day for a total of five times during a 2-week cycle (Group B)
Number of subjects: 47
Study 21322147 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day) and Fluoxetine (20 mg/day) for 6 months
Number of subjects: 280
Study 21322147 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone and Fluoxetine placebo
Number of subjects: 280
Study 21322147 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone placebo and Fluoxetine
Number of subjects: 280
Study 21322147 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone placebo and Fluoxetine placebo
Number of subjects: 280
Study 19107262 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulpotomy technique using formocresol as a temporary dressing and zinc oxide-eugenol cement for obturation (group 1)
Number of subjects: 51
Study 19107262 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulpectomy technique with calcium hydroxide paste as a temporary dressing and dense calcium hydroxide paste for obturation (group 2)
Number of subjects: 51
Study 19107262 — intervention group
Group type: COMPARATOR
Intervention: Both techniques (group 1 and group 2)
Number of subjects: 51
Study 16871932 — intervention group
Group type: COMPARATOR
Intervention: Topical mitomycin-C (MMC) applied at a concentration of 0.5 mg/mL for 4 minutes post-frontal sinusotomy.
Number of subjects: 0
Study 14696846 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucuronidase activity in CSF before treatment
Number of subjects: 43
Study 11154366 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus (ISBP) block
Number of subjects: 40
Study 11154366 — intervention group
Group type: COMPARATOR
Intervention: No block (Control)
Number of subjects: 40
Study 9150588 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential mode of thinking with mortality salience
Number of subjects: 0
Study 9150588 — intervention group
Group type: COMPARATOR
Intervention: Rational mode of thinking with mortality salience
Number of subjects: 0
Study 9150588 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential mode with mortality salience
Number of subjects: 0
Study 9150588 — intervention group
Group type: COMPARATOR
Intervention: Rational mode with mortality salience
Number of subjects: 0
Study 7944244 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam with nalbuphine
Number of subjects: 40
Study 7944244 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40
Study 3591425 — intervention group
Group type: EXPERIMENTAL
Intervention: Fronto-frontal ECT (FF)
Number of subjects: 0
Study 3591425 — intervention group
Group type: COMPARATOR
Intervention: Temporo-parietal ECT (TP)
Number of subjects: 0
Study 15235963 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion of 0.25% bupivacaine at a rate of 2‐5 ml.hr(‐1)
Number of subjects: 16
Study 15235963 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.125% or 0.25% bupivacaine and 0.0025% or 0.005% morphine at a rate of 2‐4 ml.hr(‐1)
Number of subjects: 16
Study 788570 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin plus isoniazid plus rifampicin
Number of subjects: 673
Study 788570 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid plus rifampicin
Number of subjects: 673
Study 788570 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin, isoniazid, rifampicin, and pyrazinamide followed by thiacetazone plus isoniazid
Number of subjects: 673
Study 788570 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin plus isoniazid plus pyrazinamide twice a week
Number of subjects: 673
Study 31811006 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted eHealth strategy (mobile website, digital newsletters, social media)
Number of subjects: 779
Study 31811006 — intervention group
Group type: COMPARATOR
Intervention: Usual care (digital patient information letter)
Number of subjects: 779
Study 31811006 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted eHealth strategy
Number of subjects: 779
Study 31811006 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 779
Study 28656713 — intervention group
Group type: EXPERIMENTAL
Intervention: 90:10 deproteinized bovine bone (DPBB) and autogenous bone (AB) mixture
Number of subjects: 13
Study 28656713 — intervention group
Group type: EXPERIMENTAL
Intervention: 60:40 deproteinized bovine bone (DPBB) and autogenous bone (AB) mixture
Number of subjects: 13
Study 28656713 — intervention group
Group type: COMPARATOR
Intervention: Both mixtures (90:10 and 60:40)
Number of subjects: 13
Study 26555123 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone and mailed outreach individualized based on cardiovascular disease risk and uncontrolled risk factors provided by lay health workers.
Number of subjects: 646
Study 26555123 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 646
Study 26555123 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable.
Number of subjects: 646
Study 23216520 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation programme for 9 months
Number of subjects: 20
Study 23216520 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 21252501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic injection of AM-101
Number of subjects: 0
Study 21252501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20137557 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium- and long-chain fatty acid triacylglycerol (MLCT)
Number of subjects: 101
Study 20137557 — intervention group
Group type: COMPARATOR
Intervention: Long-chain fatty acid triacylglycerol (LCT)
Number of subjects: 101